Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program
Xencor, announced it has entered into a research and license agreement in which Astellas Pharma Inc. will access Xencor’s bispecific technology to advance a novel bispecific antibody…
Read More...
Read More...
